Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere J C, Le Fur G
Sanofi Recherche, Montpellier, France.
Mol Pharmacol. 1993 Jan;43(1):84-9.
Adaptive changes in 5-hydroxytryptamine (5-HT)2 receptors were investigated in mice after repeated administration of SR 46349B, a potent, selective, and competitive 5-HT2 receptor antagonist (Kl = 0.72 +/- 0.05 nM). Repeated administration (twice per day for 3 days and once on the morning of the fourth day) of SR 46349B (5 or 10 mg/kg, orally) caused 24 hr later a marked increase in 5-HT2 receptor number (+41% and +75%, respectively), measured ex vivo in brain cortical membranes with [3H] ketanserin, without affecting its affinity constant. Further, administration of the 5-HT2 agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane produced, in SR 46349B (10 mg/kg, orally)-treated mice, a significant stimulation of the 5-HT2 receptor-linked phosphoinositide turnover in vivo in the brain. In addition, subacute administration of SR 46349B (5 or 10 mg/kg, orally) caused a significant increase of the head-twitch response to L-5-hydroxytryptophan. This enhanced response was blocked by an acute administration of ritanserin (1 mg/kg). These results show that repeated administration of SR 46349B produced a parallel enhancement in 5-HT2 receptor number, in 5-HT2 receptor-linked signal transduction, and in 5-HT2 receptor-mediated behavioral responses in mice. These findings suggest for the first time that an up-regulation of 5-HT2 receptors can occur after repeated treatment with a selective 5-HT2 antagonist.
在反复给予强效、选择性和竞争性5-羟色胺(5-HT)2受体拮抗剂SR 46349B(Kl = 0.72 +/- 0.05 nM)后,对小鼠体内5-HT2受体的适应性变化进行了研究。反复给予SR 46349B(5或10 mg/kg,口服,每天两次,共3天,并在第四天早晨给药一次),24小时后,用[3H]酮色林对脑皮质膜进行体外测量,发现5-HT2受体数量显著增加(分别增加41%和75%),但其亲和常数未受影响。此外,在经SR 46349B(10 mg/kg,口服)处理的小鼠中,给予5-HT2激动剂(+/-)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷可在体内显著刺激脑内与5-HT2受体相关的磷酸肌醇代谢。另外,亚急性给予SR 46349B(5或10 mg/kg,口服)可使对L-5-羟色氨酸的头部抽搐反应显著增加。这种增强的反应可被急性给予利坦色林(1 mg/kg)阻断。这些结果表明,反复给予SR 46349B可使小鼠体内5-HT2受体数量、与5-HT2受体相关的信号转导以及5-HT2受体介导的行为反应同时增强。这些发现首次提示,用选择性5-HT2拮抗剂反复治疗后可能会发生5-HT2受体的上调。